In the phase III MIRASOL trial (NCT04209855), researchers compared the efficacy of mirvetuximab soravtansine versus chemotherapy in patients with platinum‐resistant, advanced high‐grade epithelial ovarian, primary peritoneal, or fallopian tube cancers expressing high FRα.259. The gene discussed is FOLR1; the disease is fallopian tube cancer.